Literature DB >> 7486863

Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells.

F Zipp1, F Weber, S Huber, S Sotgiu, A Czlonkowska, E Holler, E Albert, E H Weiss, H Wekerle, R Hohlfeld.   

Abstract

Lymphotoxin (LT) and tumor necrosis factor-alpha (TNF-alpha) play an important role in the pathogenesis of multiple sclerosis (MS). MS is associated with the HLA-DR2, Dw2, DQ6 HLA class II haplotype. Because both LT and TNF-alpha are encoded in the HLA region, the HLA association of MS may be related to the production of these cytokines. To test this hypothesis, we investigated the production of LT, TNF-alpha, and interferon-gamma (IFN-gamma) by CD4+ T-cell lines (TCLs) specific for myelin basic protein (MBP) or tetanus toxoid (TT) isolated from MS patients and normal controls. After stimulation with specific antigen but not mitogen, TCLs from HLA-DR2+ donors produced significantly more LT and TNF-alpha than TCLs from DR2- donors. In contrast, HLA-DR2+ and DR2- TCLs did not differ in the production of IFN-gamma, a cytokine also produced by T cells but not encoded in the HLA region. Increased secretion of LT and TNF-alpha was unrelated to the specificity (MBP vs TT), MHC restriction (HLA-DR2 vs other DR molecules), or source (MS vs normal) of the TCLs. There was no significant association of the cytokine production with individual LT or TNF-alpha alleles, indicating that the increased production of these cytokines may be linked to other polymorphic genes in this region. The results suggest that the association of MS with HLA-DR2 implies a genetically determined propensity of T cells to produce increased amounts of LT and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7486863     DOI: 10.1002/ana.410380506

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis.

Authors:  R W Ledeen; G Chakraborty
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

4.  The polymorphisms of the TNF-α gene in multiple sclerosis?--a meta-analysis.

Authors:  Lidan Xu; Weiguang Yuan; Haiming Sun; Xuelong Zhang; Xueyuan Jia; Chao Shen; Yanling Zhao; Donglin Sun; Yang Yu; Yan Jin; Songbin Fu
Journal:  Mol Biol Rep       Date:  2010-12-07       Impact factor: 2.316

5.  Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination.

Authors:  Roberta Brambilla; Jessica Jopek Ashbaugh; Roberta Magliozzi; Anna Dellarole; Shaffiat Karmally; David E Szymkowski; John R Bethea
Journal:  Brain       Date:  2011-09       Impact factor: 13.501

6.  HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.

Authors:  L F Barcellos; J R Oksenberg; A B Begovich; E R Martin; S Schmidt; E Vittinghoff; D S Goodin; D Pelletier; R R Lincoln; P Bucher; A Swerdlin; M A Pericak-Vance; J L Haines; S L Hauser
Journal:  Am J Hum Genet       Date:  2003-01-28       Impact factor: 11.025

7.  Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1.

Authors:  A P Kallaur; S R Oliveira; A N C Simão; E R D de Almeida; H K Morimoto; J Lopes; L M Pelegrino; W L C J de Pereira; Daniele Frizon Alfieri; R M Andrade; S D Borelli; M A E Watanabe; D R Kaimen-Maciel; E M V Reiche
Journal:  J Mol Neurosci       Date:  2014-04-04       Impact factor: 3.444

8.  Tumor Necrosis Factor-Alpha (TNF-α-308 G>A) Polymorphism in High-grade Gliomas.

Authors:  Selçuk Ozdogan; Cumhur Kaan Yaltirik; Seda Gulec Yilmaz; Mustafa Kaya; Ali Haluk Duzkalir; Nail Demirel; Ali Kafadar; Turgay Isbir
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

9.  Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice.

Authors:  D Sean Riminton; H Körner; D H Strickland; F A Lemckert; J D Pollard; J D Sedgwick
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.